Supreme Court Strengthens Generic Liability Shield; FDA Reg Change Could Create Opening
This article was originally published in The Pink Sheet Daily
Executive Summary
The high court rules 5-4 that generic drug makers cannot be sued for alleged design defects based on the adequacy of a drug’s label warnings; FDA continues to discuss revising its regulations to allow generic companies to change their labeling.